Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Linzagolix

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Apotex Secures Exclusive Canadian Rights For
    Apotex Secures Exclusive Canadian Rights For "Linzagolix"

    07 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/apotex-strengthens-commitment-to-womens-health-with-exclusive-canadian-rights-to-linzagolix-for-uterine-fibroid-treatment-302577166.html

    PR NEWSWIRE
    07 Oct 2025
    Share Share
    ObsEva Scraps Plans for Uterine Fibroid Candidate
    ObsEva Scraps Plans for Uterine Fibroid Candidate

    02 Aug 2022

    // FDANEWS

    https://www.fdanews.com/articles/208842-obseva-scraps-plans-for-uterine-fibroid-candidate?v=preview

    FDANEWS
    02 Aug 2022
    Share Share
    Women's health firm launches major reorg after ominous FDA note
    Women's health firm launches major reorg after ominous FDA note

    28 Jul 2022

    // Angus Liu FIERCEPHARMA

    https://www.fiercepharma.com/pharma/ominous-fda-talks-obseva-scraps-lead-womens-health-drug-plots-layoffs-major-restructuring

    Angus Liu FIERCEPHARMA
    28 Jul 2022
    Share Share
    ObsEva Announces UK MHRA Marketing Authorization for Yselty in Uterine Fibroids
    ObsEva Announces UK MHRA Marketing Authorization for Yselty in Uterine Fibroids

    28 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/28/2470795/0/en/ObsEva-Announces-UK-MHRA-Marketing-Authorization-for-Yselty-linzagolix-an-Oral-GnRH-Antagonist-for-the-Treatment-of-Uterine-Fibroids.html

    GLOBENEWSWIRE
    28 Jun 2022
    Share Share
    Theramex Announces EC Marketing Authorization for Yselty in Uterine Fibroids
    Theramex Announces EC Marketing Authorization for Yselty in Uterine Fibroids

    17 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220617005176/en

    BUSINESSWIRE
    17 Jun 2022
    Share Share
    ObsEva Presents Data on Oral GnRH Antagonist Linzagolix
    ObsEva Presents Data on Oral GnRH Antagonist Linzagolix

    25 May 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/05/25/2449884/0/en/ObsEva-Presents-Clinical-Data-on-Oral-GnRH-Antagonist-Linzagolix-at-Multiple-Congresses.html

    GLOBENEWSWIRE
    25 May 2022
    Share Share